ATE227268T1 - Alpha v beta 3 antagonisten - Google Patents

Alpha v beta 3 antagonisten

Info

Publication number: ATE227268T1
Authority: AT; Austria
Prior art keywords: beta; alpha; antagonists; compounds; inhibiting
Prior art date: 1996-04-10

Application number

AT97920270T

Other languages

English (en)

Inventor

Mark E Duggan

George D Hartman

William F Hoffman

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-10

Filing date

1997-04-08

Publication date

2002-11-15

1996-05-24 Priority claimed from GBGB9610996.2A external-priority patent/GB9610996D0/en

1997-04-08 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

2002-11-15 Application granted granted Critical

2002-11-15 Publication of ATE227268T1 publication Critical patent/ATE227268T1/de

Links

239000005557 antagonist Substances 0.000 title 1
230000002401 inhibitory effect Effects 0.000 abstract 2
239000002464 receptor antagonist Substances 0.000 abstract 2
229940044551 receptor antagonist Drugs 0.000 abstract 2
201000001320 Atherosclerosis Diseases 0.000 abstract 1
208000006386 Bone Resorption Diseases 0.000 abstract 1
206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
230000033115 angiogenesis Effects 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
230000024279 bone resorption Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
XTBAPWCYTNCZTO-UHFFFAOYSA-N isoindol-1-one Chemical class C1=CC=C2C(=O)N=CC2=C1 XTBAPWCYTNCZTO-UHFFFAOYSA-N 0.000 abstract 1
208000002780 macular degeneration Diseases 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
230000004614 tumor growth Effects 0.000 abstract 1
230000002792 vascular Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)

AT97920270T 1996-04-10 1997-04-08 Alpha v beta 3 antagonisten ATE227268T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US1517796P	1996-04-10	1996-04-10
GBGB9610996.2A GB9610996D0 (en)	1996-05-24	1996-05-24	µv›3 Antagonists
PCT/US1997/005890 WO1997037655A1 (en)	1996-04-10	1997-04-08	αvβ3 ANTAGONISTS

Publications (1)

Publication Number	Publication Date
ATE227268T1 true ATE227268T1 (de)	2002-11-15

Family

ID=26309398

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97920270T ATE227268T1 (de)	1996-04-10	1997-04-08	Alpha v beta 3 antagonisten

Country Status (8)

Country	Link
EP (1)	EP0901373B1 (de)
JP (1)	JP2000508319A (de)
AT (1)	ATE227268T1 (de)
AU (1)	AU720758B2 (de)
CA (1)	CA2251017A1 (de)
DE (1)	DE69716900T2 (de)
ES (1)	ES2185009T3 (de)
WO (1)	WO1997037655A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9708265D0 (en) *	1997-04-24	1997-06-18	Nycomed Imaging As	Contrast agents
ATE236626T1 (de) *	1996-10-30	2003-04-15	Merck & Co Inc	Integrin antagonist
US6017926A (en) *	1997-12-17	2000-01-25	Merck & Co., Inc.	Integrin receptor antagonists
US6048861A (en)	1997-12-17	2000-04-11	Merck & Co., Inc.	Integrin receptor antagonists
US6066648A (en) *	1997-12-17	2000-05-23	Merck & Co., Inc.	Integrin receptor antagonists
US6211191B1 (en)	1997-12-17	2001-04-03	Merck & Co., Inc.	Integrin receptor antagonists
KR20010042587A (ko)	1998-04-09	2001-05-25	기따자또 이찌로	인테그린 알파브이베타3 길항제로서 아미노피페리딘 유도체
ATE253061T1 (de) *	1998-06-29	2003-11-15	Iaf Biochem Int	Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide
HUP0104509A3 (en) *	1998-07-06	2002-05-28	Scripps Research Inst	Angiogenesis inhibiting nitroaryl-derivatives process for their preparation and their use
JP2002522540A (ja) *	1998-08-13	2002-07-23	メルクエンドカムパニーインコーポレーテッド	インテグリン受容体拮抗薬
PT1123283E (pt)	1998-10-22	2004-09-30	Hoffmann La Roche	Derivados de tiazole
SE9803773D0 (sv) *	1998-11-05	1998-11-05	Astra Pharma Prod	Compounds
HUP0203338A2 (hu)	1999-04-13	2003-03-28	Abbott Gmbh & Co. Kg	Integrin receptor ligandumok
DK1187592T3 (da)	1999-06-02	2007-11-05	Merck & Co Inc	Alfa v-integrinreceptorantagonister
EP1187825A1 (de)	1999-06-07	2002-03-20	Shire Biochem Inc.	Thiophen integrin inhibitoren
EP1198231A1 (de)	1999-07-21	2002-04-24	American Home Products Corporation	Bicyklischer antagonist selektiv für (alpha)v (beta)3 integrin
EP1209152A4 (de)	1999-08-05	2003-03-12	Meiji Seika Kaisha	Omega-amino-alpha-hydroxy-carbonsäure-derivate mit einem integrin alpha v beta antagonismus
DE10006139A1 (de)	2000-02-11	2001-08-16	Merck Patent Gmbh	Indol-3-yl-Derivate
ES2366775T3 (es)	2001-04-24	2011-10-25	Merck Patent Gmbh	POLITERAPIA UTILIZANDO AGENTES ANTIANGIOGÉNICOS Y TNF(alfa).
US7361773B2 (en)	2002-03-12	2008-04-22	Wyeth	Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
ATE439356T1 (de)	2002-03-12	2009-08-15	Wyeth Corp	Verfahren zur herstellung von chiralen n-aryl piperazinen
MXPA04008730A (es)	2002-03-12	2004-12-06	Wyeth Corp	Proceso para preparacion de piperazinas quirales 1,4-disustituidas.
ATE360002T1 (de) *	2002-03-12	2007-05-15	Wyeth Corp	Verfahren zur herstellung von n1-(2'-pyridyl)-1,2-propandiaminsulfamidsäure und ihre verwendung zur herstellung von biologisch aktiven piperazinen
US7091349B2 (en)	2002-03-12	2006-08-15	Wyeth	Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution
WO2005054188A1 (en) *	2003-12-02	2005-06-16	Ucb, S.A.	Imidazole derivatives, processes for preparing them and their uses
AU2007207465B2 (en)	2006-01-18	2012-12-06	Merck Patent Gmbh	Specific therapy using integrin ligands for treating cancer
BRPI0806596A2 (pt)	2007-01-18	2013-07-23	Merck Patent Ges Mit Berchraenkter Haftung	medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer
EP2445534A2 (de)	2009-05-25	2012-05-02	Merck Patent GmbH	Kontinuierliche verabreichung von cilengitid in der krebstherapie
MX2014008373A (es) *	2012-01-27	2014-09-26	Hoffmann La Roche	Conjugados antagonistas de integrina para suministro dirigido a celulas que expresan alfa-v-beta-3.
ES2864079T3 (es)	2014-05-30	2021-10-13	Pfizer	Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
WO2023275715A1 (en)	2021-06-30	2023-01-05	Pfizer Inc.	Metabolites of selective androgen receptor modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4505911A (en) *	1983-10-13	1985-03-19	Mead Johnson & Company	Isoindole diuretic derivatives, compositions and use
US5272158A (en) *	1991-10-29	1993-12-21	Merck & Co., Inc.	Fibrinogen receptor antagonists
DE4414880A1 (de) *	1994-04-28	1995-11-02	Basf Ag	Schwefelverbindungen
US5646000A (en) *	1994-09-29	1997-07-08	Merck & Co., Inc.	Compounds and methods for identifying activated platelets
KR19990076877A (ko) *	1995-12-29	1999-10-25	스티븐 베네티아너	비트로넥틴 수용체 길항제
CN1209060A (zh) *	1995-12-29	1999-02-24	史密丝克莱恩比彻姆公司	玻连蛋白受体拮抗剂
EP0973396A4 (de) *	1997-04-07	2001-02-07	Merck & Co Inc	Verfahren zur behandlung von krebs

1997
- 1997-04-08 CA CA002251017A patent/CA2251017A1/en not_active Abandoned
- 1997-04-08 WO PCT/US1997/005890 patent/WO1997037655A1/en not_active Ceased
- 1997-04-08 DE DE69716900T patent/DE69716900T2/de not_active Expired - Fee Related
- 1997-04-08 EP EP97920270A patent/EP0901373B1/de not_active Expired - Lifetime
- 1997-04-08 AU AU24501/97A patent/AU720758B2/en not_active Ceased
- 1997-04-08 ES ES97920270T patent/ES2185009T3/es not_active Expired - Lifetime
- 1997-04-08 AT AT97920270T patent/ATE227268T1/de not_active IP Right Cessation
- 1997-04-08 JP JP9536469A patent/JP2000508319A/ja active Pending

Also Published As

Publication number	Publication date
ES2185009T3 (es)	2003-04-16
EP0901373A1 (de)	1999-03-17
CA2251017A1 (en)	1997-10-16
WO1997037655A1 (en)	1997-10-16
EP0901373A4 (de)	1999-07-07
EP0901373B1 (de)	2002-11-06
DE69716900T2 (de)	2003-07-03
AU2450197A (en)	1997-10-29
AU720758B2 (en)	2000-06-08
JP2000508319A (ja)	2000-07-04
DE69716900D1 (de)	2002-12-12

Legal Events

Date	Code	Title	Description
2003-05-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69716900D1 (de)	2002-12-12	Alpha v Beta 3 ANTAGONISTEN
ES2194223T3 (es)	2003-11-16	Antagonistas de la integrina.
ATE298338T1 (de)	2005-07-15	Integrin-rezeptor-antagonisten
DE69829996D1 (de)	2005-06-02	Integrin-rezeptor-antagonisten
DE69830806D1 (de)	2005-08-11	Integrinrezeptor antagonisten
CA2277273A1 (en)	1998-07-23	Integrin antagonists
HRP20010895A2 (en)	2003-08-31	Alpha v integrin receptor antagonists
AU7793501A (en)	2002-02-05	Alpha v integrin receptor antagonists
IL147442A0 (en)	2002-08-14	Promotion or inhibition of angiogenesis and cardiovscularization by tumor necrosis factor ligand/receptor homologs
WO2002090325A3 (en)	2003-02-27	Benzazepinone alpha v integrin receptor antagonists
YU38300A (sh)	2002-12-10	Antagonisti integrinskog receptora
YU38200A (sh)	2003-12-31	Antagonisti integrinskog receptora